English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

See related article, pp 148–154Peripheral artery disease (PAD) has been for many years a chapter in cardiovascular diseases that did not attract the interest of clinicians. Intermittent claudication, the most common clinical manifestation of PAD, was considered a rather unimportant symptom. Several new findings published during the last decade have profoundly changed our views on PAD.1 First, intermittent claudication significantly impacts on the quality of life and on the activities of the patients experiencing it. Moreover, and at least as important, a number of large-scale studies and registries unraveled severely increased risk for coronary and cerebrovascular morbidity and mortality in PAD patients.2 In fact, this should not surprise us, because the most frequent cause of PAD is, by far, atherosclerosis. The increased risk is of particular importance, because many patients with proven PAD are completely asymptomatic. In such cases, PAD is only detected by clinical examination (absent peripheral pulses) or by measuring ankle brachial pressure index. Whichever way they are detected, the increased risk is present whether the disease is symptomatic or not. Therefore, with all of this in mind, physicians and scientists alike start to realize that PAD should be seen not only as a local problem but also as a marker of atherosclerosis elsewhere in the body.As a consequence, treatment of PAD patients should be oriented at symptoms, if present, but above all, at controlling total CV risk (Table). Symptoms of intermittent claudication are best treated …

Can We Use β-Blocking Agents in Patients With Peripheral Artery Disease?